Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Proteogenetic drug response profiling elucidates targetable vulnerabilities of myelofibrosis.

Nature communications - 12 Oct 2023

Wildschut Mattheus H E, Mena Julien, Dördelmann Cyril, van Oostrum Marc, Hale Benjamin D, Settelmeier Jens, Festl Yasmin, Lysenko Veronika, Schürch Patrick M, Ring Alexander, Severin Yannik, Bader Michael S, Pedrioli Patrick G A, Goetze Sandra, van Drogen Audrey, Balabanov Stefan, Skoda Radek C, Lopes Massimo, Wollscheid Bernd, Theocharides Alexandre P A, Snijder Berend

Abstract excerpt

Myelofibrosis is a hematopoietic stem cell disorder belonging to the myeloproliferative neoplasms. Myelofibrosis patients frequently carry driver mutations in either JAK2 or Calreticulin (CALR) and have limited therapeutic options. Here, we integrate ex vivo drug response and proteotype analyses across myelofibrosis patient cohorts to discover targetable vulnerabilities and associated therapeutic strategies. Drug...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Calreticulin
Share to Hematopoietic Stem Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Homozygote

Share to Janus Kinase 2

Share to Mutation

Share to Myeloproliferative Disorders

Share to Primary Myelofibrosis

Source

Open in PubMed Open full text

Identifiers

PMID: 37828014
DOI: 10.1038/s41467-023-42101-z
PMCID: PMC10570306

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Proteogenetic drug response profiling elucidates targetable vulnerabilities of myelofibrosis.PMID 37828014Read ↗

Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myelomaSemantic proximity Read ↗

Targeted single-cell RNA sequencing analysis reveals metabolic reprogramming and the ferroptosis-resistant state in hematologic malignancies.Semantic proximity Read ↗

Broad Next-Generation Integrated Sequencing of Myelofibrosis Identifies Disease-Specific and Age-Related Genomic Alterations.Semantic proximity Read ↗

Mapping the proteogenomic landscape enables prediction of drug response in acute myeloid leukemia.Semantic proximity Read ↗

Single-cell landscape of innate and acquired drug resistance in acute myeloid leukemiaSemantic proximity Read ↗

Drug-perturbation-based stratification of blood cancerSemantic proximity Read ↗

Dominant COSMIC Mutational Signatures and Unsupervised Machine Learning Define Mechanism-Based Therapeutic Stratification in Blast-Crisis CML: Implications in Precision Medicine of Relapsed and Refractory CancersSemantic proximity Read ↗

Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisionsSemantic proximity Read ↗

Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory.Semantic proximity Read ↗

Single-cell methods in myeloproliferative neoplasms: old questions, new technologies.Semantic proximity Read ↗

Human gene-engineered calreticulin mutant stem cells recapitulate MPN hallmarks and identify targetable vulnerabilities.Semantic proximity Read ↗

Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.